[
    [
        {
            "time": "",
            "original_text": "【药咖君】罕见肺部疾病首款疗法获批；56亿销售额，石药王牌迎来首个对手；豪森拿下首仿；BI、武田、正大天晴、绿叶",
            "features": {
                "keywords": [
                    "罕见肺部疾病",
                    "首款疗法获批",
                    "56亿销售额",
                    "石药王牌",
                    "首个对手",
                    "豪森首仿",
                    "BI",
                    "武田",
                    "正大天晴",
                    "绿叶"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【药咖君】罕见肺部疾病首款疗法获批；56亿销售额，石药王牌迎来首个对手；豪森拿下首仿；BI、武田、正大天晴、绿叶",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]